ASND Quote, Financials, Valuation and Earnings

Cellectis SA has a net margin of -28.55% compared to Ascendis Pharma A/S's net margin of 1.68%. Ascendis Pharma A/S's return on equity of -880.05% beat Cellectis SA's return on equity of -31.08%.

Ascendis Pharma A/S has a consensus price target of $262.09, signalling upside risk potential of 22.91%. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 48.76%. Given that Cellectis SA has higher upside potential than Ascendis Pharma A/S, analysts believe Cellectis SA is more attractive than Ascendis Pharma A/S.

Ascendis Pharma A/S has a beta of 0.456, which suggesting that the stock is 54.4% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.823, suggesting its more volatile than the S&P 500 by 182.278%.

Ascendis Pharma A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma A/S pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Ascendis Pharma A/S quarterly revenues are $249.6M, which are larger than Cellectis SA quarterly revenues of $35M. Ascendis Pharma A/S's net income of -$71.3M is lower than Cellectis SA's net income of $586.4K. Notably, Ascendis Pharma A/S's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma A/S is 17.83x versus 6.02x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -28.55% compared to Ascendis Pharma A/S's net margin of --. Ascendis Pharma A/S's return on equity of -880.05% beat DBV Technologies SA's return on equity of -280.59%.

Ascendis Pharma A/S has a consensus price target of $262.09, signalling upside risk potential of 22.91%. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 107.86%. Given that DBV Technologies SA has higher upside potential than Ascendis Pharma A/S, analysts believe DBV Technologies SA is more attractive than Ascendis Pharma A/S.

Ascendis Pharma A/S has a beta of 0.456, which suggesting that the stock is 54.4% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.

Ascendis Pharma A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma A/S pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Ascendis Pharma A/S quarterly revenues are $249.6M, which are larger than DBV Technologies SA quarterly revenues of --. Ascendis Pharma A/S's net income of -$71.3M is lower than DBV Technologies SA's net income of -$33M. Notably, Ascendis Pharma A/S's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma A/S is 17.83x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion AS has a net margin of -28.55% compared to Ascendis Pharma A/S's net margin of -64.14%. Ascendis Pharma A/S's return on equity of -880.05% beat Evaxion AS's return on equity of --.

Ascendis Pharma A/S has a consensus price target of $262.09, signalling upside risk potential of 22.91%. On the other hand Evaxion AS has an analysts' consensus of $14.19 which suggests that it could grow by 197.43%. Given that Evaxion AS has higher upside potential than Ascendis Pharma A/S, analysts believe Evaxion AS is more attractive than Ascendis Pharma A/S.

Ascendis Pharma A/S has a beta of 0.456, which suggesting that the stock is 54.4% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ascendis Pharma A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma A/S pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

Ascendis Pharma A/S quarterly revenues are $249.6M, which are larger than Evaxion AS quarterly revenues of $37.5K. Ascendis Pharma A/S's net income of -$71.3M is lower than Evaxion AS's net income of -$4.9M. Notably, Ascendis Pharma A/S's price-to-earnings ratio is -- while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma A/S is 17.83x versus 3.20x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of -28.55% compared to Ascendis Pharma A/S's net margin of 26.68%. Ascendis Pharma A/S's return on equity of -880.05% beat Novo Nordisk A/S's return on equity of 68.76%.

Ascendis Pharma A/S has a consensus price target of $262.09, signalling upside risk potential of 22.91%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.33 which suggests that it could grow by 5.18%. Given that Ascendis Pharma A/S has higher upside potential than Novo Nordisk A/S, analysts believe Ascendis Pharma A/S is more attractive than Novo Nordisk A/S.

Ascendis Pharma A/S has a beta of 0.456, which suggesting that the stock is 54.4% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.529%.

Ascendis Pharma A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.4% to investors and pays a quarterly dividend of $0.58 per share. Ascendis Pharma A/S pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ascendis Pharma A/S quarterly revenues are $249.6M, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Ascendis Pharma A/S's net income of -$71.3M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Ascendis Pharma A/S's price-to-earnings ratio is -- while Novo Nordisk A/S's PE ratio is 14.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma A/S is 17.83x versus 4.85x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.